Vitamin D related genetic polymorphisms affect serological response to high-dose vitamin D supplementation in multiple sclerosis.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of multiple sclerosis.

Here, the researchers explore whether vitamin D-associated SNPs and MS risk alleles confound serological response to vitamin D supplementation.

Who Took Part

The study group was 34 participants.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

34 participants from the SOLARIUM study consented to genotyping, of which 26 had vitamin D data available.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

The subject headings attached to it are 25-Hydroxyvitamin D3 1-alpha-Hydroxylase, DNA-Binding Proteins, Dietary Supplements, Genotype, Multiple Sclerosis, Relapsing-Remitting, Polymorphism, Single Nucleotide and Prognosis.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 34 participants in people with multiple sclerosis.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (PloS one), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Multiple sclerosis research.